image description

Tag: Chandra Mohan

New Approach to Treating Lupus Nephritis

February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […] Read More

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] Read More

The LRA’s Forum for Discovery: Sharing the Latest News in Lupus Research

The Lupus Research Alliance (LRA) held our annual scientific conference, the Forum for Discovery, online in true 2020 fashion. More than 150 funded investigators, scientific advisors, and partners from the pharmaceutical and biotech industries logged on from their computers around the world to hear about new discoveries from LRA-funded researchers. LRA President Ken Farber emphasized […] Read More

Lupus Research Program – Driven by LRA Advocacy – Announces 10 New Grant Recipients

March 19, 2021 Ten new applications for promising scientific studies were just recommended for funding by the Lupus Research Program (LRP) within the Department of Defense! The dedicated Lupus Research Program was first established in 2017 under the Congressionally Directed Medical Research Programs operated by the Army Medical Research and Materiel Command in Ft. Detrick, […] Read More

LRA Congratulates Equillium on Positive Results of Study of Potential New Lupus Treatment

March 30, 2021 Equillium, Inc. announced positive topline data from the phase 1b EQUALISE study in patients with systemic lupus erythematosus (SLE).  This study suggests that itolizumab, a monoclonal antibody selectively targeting the CD6-ALCAM pathway, was safe and well tolerated among people with SLE. [Source: Equillium, Inc. Press Release 3.30.21] The EQUALISE study is evaluating […] Read More

LRA Pleased to Share News of Lupus Nephritis Clinical Trial Launch

October 1, 2019 The Lupus Research Alliance is pleased to share news about the launch of EQUALISE, a Phase 1b trial that will evaluate the safety and tolerability of an experimental compound itolizumab at various doses in a small group of patients with systemic lupus erythematosus (SLE) and lupus nephritis. Sponsored by the biotechnology company […] Read More

LRA-Funded Researcher Finds New Biomarkers for Lupus Nephritis

August 7, 2019 Dr. Chandra Mohan discovered that blood clotting proteins are higher in the urine of people with lupus nephritis, announced University of Houston. His work showed that both proteins that promote clotting and those that work to dissolve them are involved.  He began examining these proteins because people with lupus and lupus nephritis […] Read More